Goodwin Advises VectorY Therapeutics on Raising €74.5 Million ($83.5 Million)

The Life Sciences team advised VectorY Therapeutics on raising €74.5 million ($83.5 million) in new financing to advance its clinical and preclinical pipeline. The financing includes new investors Angelini Ventures, Invest-NL, and the European Investment Bank, alongside returning investors Forbion, EQT Life Sciences, MRL Ventures, Insight Partners, BGV, Eli Lilly and Company, and the ALS Investment Fund. Proceeds will support the advancement of VectorY’s lead program, VTx-002, through key clinical milestones, including the final readout of the PIONEER-ALS® Phase 1/2 clinical study, as well as VectorY’s broader pipeline. 

VectorY Therapeutics is dedicated to changing the trajectory of neurodegenerative diseases by developing precision-targeted, durable therapies that have the potential to arrest and ultimately reverse disease progression. With deep expertise in neurobiology, antibody engineering, and AAV-based delivery and manufacturing, VectorY is building a pipeline that includes VTx-002 targeting TDP-43 in ALS, VTx-003 targeting mutant HTT in Huntington’s disease, VTx-004 targeting TDP-43 in frontotemporal dementia (FTD), and VTx-005 targeting phosphorylated tau in Alzheimer’s disease.

The Goodwin team was led by Michael Bison, Marishka DeToy, Ana Gentil Zattar, and Steven Dilsizian.

For more information on the deal, please read the press release.